Helix Enters Multi-Year Partnership with Alnylam to Enhance Precision Medicine Initiatives Helix and Alnylam have announced a strategic partnership to leverage genomic data and drive advancements in precision medicine. This collaboration aims to revolutionize RNAi therapeutics.

Helix Enters Multi-Year Partnership with Alnylam to Enhance Precision Medicine Initiatives #United_States #San_Mateo #Helix #Alnylam #GenoSphere

34-35 PHARMA - Time capsule Time capsule. The ten groundbreaking drugs shaping 2025 and the future

#Vertex #Cysticfibrosis #AstraZeneca #DaiichiSankyo #lungcancer #breastcancer #painmanagement #Alnylam #Sanofi #Haemophilia #Genentech #Roche #MS #MSD #Hypercholesterolemia #Pfizer #InnoventBiologics #EliLilly #Obesity #type2diabetes #GSK #eosinophilicasthma #meningitisvaccine
zurl.co/bzBzK

#RNAi pure-plays #Alnylam and #SilenceTherapeutics continue moving higher.

Alnylam soon worth more than #Regeneron. Oligos still much less #China exposure compared to antibodies and CAR-Ts. Me-thinks we'll see eye-cathing M&A soon.

#Alnylam trades at a 50x market cap of #Intellia directly exposed to CRISPR for many of its high-value liver indications.

How on earth do they not have strategic option to #CRISPR, even through a 50:50-type partnership with a leading CRISPR Co if not in-house?

#RNAediting similar situation.

The reason why I'm hesitant about the near-term of #Alnylam (and why they should use their market cap heft while it lasts) is that the list price of #AMVUTTRA is twice that of #ATTRUBY and #VYNDAQEL... not sure how that is sustainable.

Mark this post: #Alnylam will regret not having done #CRISPR deals during this downturn. Ideal life-cycle, market segmentation complement. #Ionis has done it before with #Metagenomi. Metagenomi trades 70% below cash.

Alnylam stock rises following CHMP’s positive opinion on Amvuttra Investing.com -- Shares of Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) climbed 4% following the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommendation to extend the marketing authorization for its drug Amvuttra. The positive opinion, announced on April 25, 2025, supports the use of Amvuttra in treating both wild-type and hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in adults. Amvuttra, which is already approved for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), has now broadened its therapeutic reach, potentially increasing its market presence in the European Union. The CHMP’s endorsement is a significant step towards full marketing authorization for this new indication, which is expected to enhance Alnylam’s product portfolio and revenue streams. The CHMP’s positive opinion is part of a broader set of recommendations for extensions of therapeutic indications for ten medicines already authorized in the EU. The committee’s recognition of Amvuttra’s potential in treating ATTR-CM is anticipated to bolster confidence in Alnylam’s capabilities in addressing rare diseases and expanding treatment options for patients with serious conditions. While Alnylam has not released an official statement regarding the financial impact of the CHMP’s recommendation, investors have responded favorably to the news. The stock’s upward movement reflects optimism about the potential for increased sales and market penetration for Amvuttra in the EU. The market’s reaction underscores the importance of regulatory approvals in shaping pharmaceutical companies’ growth trajectories. As Alnylam awaits the final decision on the marketing authorization for Amvuttra’s new indication, the company’s stock performance will likely continue to be influenced by regulatory developments and the drug’s commercial success in the European market. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Alnylam #Amvuttra #CHMP #StockMarket #Investing

#biotech I know, cash is not to be spent lightly in this environment...

....but Big Biotechs like #Alnylam ($32B market cap) might consider using their relatively strong market caps and do some shopping (targets trading well below cash).

https://www.linkedin.com/jobs/view/4193007892

Are you someone with expertise in statgen who wants to impact therapeutic development? Come join my colleagues at #alnylam! You'll get a chance to work with interdisciplinary teams with a rapid timeline from discovery to proof of concept to clinic!

t.co/egOiPBYhDj

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B Alnylam Pharmaceuticals Press Release | Mar 28, 2025

#Alnylam gets another #RNAiTherapeutic approved, this time in hemophilia (A and B) targeting anti-thrombin. Sanofi has majority rights to it.

This one was a hard slog. Commercial uptake of this prophylactic once-every-2-month subQ will be interesting.

investors.alnylam.com/press-releas...

NEWS: #Alnylam has the FDA approval it sought for Amvuttra in a form of #cardiomyopathy associated with rare disease #ATTRamyloidosis, allowing it to compete head-to-head with rival therapies from #Pfizer and #BridgeBio.

pharmaphorum.com/news/alnylam...